Tempus reported a third-quarter adjusted EBITDA of $1.5 million (first positive adjusted EBITDA), driven by Genomics volumes up 33% YoY (Oncology +27%, Hereditary +37%) and Data Licensing growth of 38% with $150 million in new total contract value; management said acquisition-related costs for Paige depressed EBITDA and without that drag adjusted EBITDA would have been near $4 million. Butterfly Network posted modest revenue growth (U.S. $16.1M; international $5.4M, +4% YoY), a normalized cash burn of $3.9M, an adjusted EBITDA loss of $8.1M and a negative gross margin of 17.5% largely due to a $17.4M inventory write-off. Valuation metrics show Tempus trading at a forward 12-month P/S of 8.18 (vs median 8.01) and BFLY at 6.45 (vs one-year median 5.55); 2025 EPS estimates narrow to -$0.65 for TEM (from -$1.58 prior year) and -$0.15 for BFLY (from -$0.34 prior year). Overall, Tempus appears to have reached an operational inflection while Butterfly shows improving efficiency but remains unprofitable, informing differentiated risk/reward profiles for investors.
Market structure: Tempus (TEM) is the primary beneficiary as recurring Data Licensing (TCV $150M) shifts revenue mix toward higher-margin, sticky streams and strengthens pricing power versus legacy labs; beneficiaries also include oncology/heritage testing customers and select AI/healthcare software providers. Losers include small-cap imaging/diagnostics peers like Butterfly (BFLY) where inventory shocks and negative gross margins compress distributor demand and weaken pricing leverage. Cross-asset: better-than-expected TEM cash generation should tighten credit spreads for comparable growth healthcare credits within 3–12 months, while BFLY’s volatility and potential refinancing needs raise implied equity vol and credit risk premia near term.
Risk assessment: Tail risks include a regulatory hit to genomic data monetization (privacy/FDA/coverage changes) that could reduce Data Licensing revenue by 30–50% over 12–24 months, and integration overruns from Paige that could subtract ~$20–50M in EBITDA over 1–2 years. Immediate risks (days–weeks) center on sentiment re-rates and option vol moves; short-term (2–6 months) hinge on next-quarter adjusted EBITDA and TCV conversion; long-term (1–3 years) depends on sustainable margin expansion and reimbursement. Hidden dependencies: hospital capital cycles, lab capacity constraints, and third-party payer contracting are second-order drivers that can flip outcomes quickly.
Trade implications: Tactical: establish a 2–3% long equity position in TEM with a 12% stop-loss and a price target implying 25–35% upside if sequential adjusted EBITDA exceeds $4M next quarter or 2025 EPS revisions continue toward -$0.65. Defensive/short: initiate a 0.5–1.5% NAV position short BFLY equity or buy a 6–9 month put spread to limit downside (size to cost = 50–150 bps NAV) with profit trigger if gross margin remains <0% next quarter. Pair trade: go dollar-neutral long TEM / short BFLY (1:1 notional) to isolate sector/systematic beta; consider selling covered calls on TEM if implied vol collapses post-earnings.
Contrarian angles: Market may be underpricing the durability of TEM’s recurring data TCV converting into subscription-like revenue—if >50% converts annually, forward P/S could re-rate toward 10x within 12–18 months. Conversely, BFLY’s write-down may be only the first of multiple adjustments; treat any bounce as tactical and require gross margin >0% and cash burn < $3M/mo for two consecutive quarters before reversing a short. Historical parallel: early-stage diagnostic winners re-rated after two consecutive profitable quarters; similar binary catalyst profile applies here and favors disciplined, catalyst-tied sizing.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
